Clinical trial · Observational
Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
Resident Doctor at Clinical Pathology Department
NCT04546945CI-TRIAL-00105905recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CD56 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- control cases
- description
- normal healthy person
- interventionNames
- Diagnostic Test: CD56
- label
- Patients
- description
- Patients with hematologic malignancies. Newly diagnosed.
- interventionNames
- Diagnostic Test: CD56
Primary outcomes (1)
- measure
- To identify the Pattern of expression of CD56 in hematologic malignancies.
- timeFrame
- 1 years
- description
- Expression of aberrant CD56 in hematologic malignancies by flowcytometry. To explore incidence of Expression of aberrant CD56 in hematologic malignancies . Correlation between this expression and outcome of the patient.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with hematologic malignancies. * Newly diagnosed Exclusion Criteria: * Patients with hematologic disorders other than hematologic malignancies.
References
Publications (0)
Data not yet available
No reference posted for this study.